Şunu aradınız:: tumor (İngilizce - Maltaca)

primary tumor type
tip ta’ tumur primarju

tumor response rate (%)
ir-rata tar-rispons tat-tumur

tumor lysis syndrome
sindrome tal-lisi tat-tumur

primary tumor type and regimen
tip ta’ tumur primarju u kors

kin tumor (melanoma), bone marrow disorder
tumur tal-ġilda (melanoma), disturb fil-mudullun

description of risk of tumor flare reaction in mcl patients
deskrizzjoni ta’ riskju ta’ reazzjoni ta’ tħarrix tat-tumur f’pazjenti b’mcl

tumor necrosis factor alpha (tnf- α) inhibitors.
inibituri tal- fattur tan- nekrosi tat- tumur (tnf- α).

- a certain benign tumor in the brain (meningioma),
-

in some cases this was not associated with apparent intra- abdominal tumor.
f’ ċertu każijiet dan ma kienx assoċjat ma ’ tumur intra- addominali apparenti.

it did not induce a proliferative response in non-haematological tumor cell lines in vitro.
huwa ma kkawżax rispons proliferattiv f’razez ta’ ċelluli tat-tumur mhux ematoloġiċi in vitro.

for any mast cell tumor treatable by syrgery, surgery should be the first choice of treatment.
għal kwalunkwe tumur tal-mast cell li jista’ jiġi kkurat b’kirurġija, il-kirurġija għandha tkun it- trattament tal-ewwel għażla.

- tumor pain,, myelodysplastic syndrome / acute myeloid leukaemia (see below)*,
-

there was a small increase in mammary fibroadenomas, a benign tumor, in male rats at the highest dose only.
bl-ogħla doża biss kien hemm żieda żgħira ta’ fibroadenoma fis-sider, tumur beninn, fil-firien irġiel.

pr = progesterone receptor a er/pr-negative or grade 3 or tumor size >5 cm
ci = confidence interval – intervall ta’ kunfidenza; er = estrogen receptor – riċettatur tal-estroġen pr = progesterone receptor – riċettatur tal-progesterone a er/pr-negattiv jew grade 3 jew daqs tat-tumur >5 cm

in subjects with measurable soft tissue disease, significantly increased numbers of complete and partial tumor responses were seen with zytiga treatment.
f’individwi b’mard fit-tessut artab li jista’ jitkejjel, dehru żidiet sinifikanti fin-numru ta’ risponsi sħaħ u parzjali tat-tumur bil-kura ta’ zytiga.

in the tumor lysis syndrome pivotal trial febuxostat 120 mg daily was administered to patients undergoing several chemotherapy regimens, including monoclonal antibodies.
fil-prova ewlenija tas-sindrome tal-lisi tat-tumur febuxostat 120 mg kuljum kien mogħti lil pazjenti b’diversi programmi ta’ kura kimoterapewtika, li jinkludu antikorpi monoklonali, mingħajr tħassib dwar is-sigurtà.

in particular, regorafenib inhibits mutated kit, a major oncogenic driver in gastrointestinal stromal tumors, and thereby blocks tumor cell proliferation.
b’mod partikolari, regorafenib jinibixxi kit mutat, fattur onkoġeniku maġġuri f’tumuri tal-istroma gastro-intestinali, u b’hekk jimblokka l-proliferazzjoni taċ-ċelluli tat-tumur.

beromun contains the active substance tasonermin (tumor necrosis factor alfa-1a), produced by recombinant dna technology.
beromun fih is-sustanza attiva tasonermin (fattur tan-nekrosi tat-tumur alfa-1a), magħmula minn teknoloġija tad-dna rikombinanti.

cases of hepatic failure, some with a fatal outcome, were observed in <1% of solid tumor patients treated with sunitinib.
każijiet ta’ insuffiċjenza tal-fwied, li wħud minnhom kienu fatali, kienu osservati f’<1% tal-pazjenti b’tumur solidu kkurati b’sunitinib.

cabozantinib exhibited dose-related tumour growth inhibition, tumor regression, and/or inhibited metastasis in a broad range of preclinical tumour models.
cabozantinib wera impediment għall-iżvilupp tat-tumur relatat mad-doża. rigressjoni tat-tumur, u/jew metastasi impeditorja f’firxa wiesgħa ta’ mudelli ta’ tumur ta’ qabel l-użu kliniku.